ASR Vermogensbeheer N.V. Has $11.07 Million Position in Stryker Corporation $SYK

ASR Vermogensbeheer N.V. grew its stake in Stryker Corporation (NYSE:SYK) by 25.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 27,978 shares of the medical technology company’s stock after acquiring an additional 5,761 shares during the period. ASR Vermogensbeheer N.V.’s holdings in Stryker were worth $11,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Goodman Advisory Group LLC acquired a new position in shares of Stryker in the first quarter valued at approximately $32,000. City Holding Co. boosted its stake in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after purchasing an additional 74 shares during the period. Ridgewood Investments LLC grew its holdings in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after buying an additional 30 shares in the last quarter. Ransom Advisory Ltd bought a new position in Stryker during the 1st quarter worth $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Stryker during the first quarter worth $40,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Up 0.6%

NYSE SYK opened at $366.50 on Friday. The business has a fifty day moving average price of $383.47 and a two-hundred day moving average price of $378.96. The stock has a market capitalization of $140.12 billion, a PE ratio of 48.54, a PEG ratio of 2.62 and a beta of 0.94. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the company earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Analyst Ratings Changes

A number of research firms recently commented on SYK. Wells Fargo & Company raised their price target on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Redburn Partners set a $420.00 target price on shares of Stryker in a report on Thursday, September 18th. Evercore ISI boosted their price target on Stryker from $390.00 to $415.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Rothschild & Co Redburn started coverage on Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. Finally, Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Fourteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $430.33.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.